Brain Diseases
Conditions
Brief summary
We are collecting brain tissue specimens and blood samples from patients at Vanderbilt University Medical Center who are undergoing intracranial surgery to remove brain tissue, including brain tumors, tissue from epilepsy surgery and brain tissue removed during surgery for other non-cancerous types of brain tissus. These specimens will then be studied using a novel microscopic laser-directed protein mass spectrometric analysis, looking for unique protein signatures.
Detailed description
We are collecting brain tissue specimens and blood samples from patients at Vanderbilt University Medical Center who are undergoing intracranial surgery to remove brain tissue, including brain tumors, tissue from epilepsy surgery and brain tissue removed during surgery for other non-cancerous types of brain tissus. These specimens will then be studied using a novel microscopic laser-directed protein mass spectrometric analysis. Data from different brain tissues including tumors of different histological sub-types will be analyzed for unique protein signatures. These protein signatures will then be statistically correlated with clinical data including time to tumor progression and response to therapy. The goal of this study is to determine molecular patterns that will be more predictive of tumor behavior, thus leading to an improved understanding of the basic biology of these poorly understood cancers. This in turn, may lead to more refined therapies and improved outcomes.
Interventions
None listed
Sponsors
Vanderbilt University Medical Center
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* A diagnosis of brain tumor or other non-cancerous tissue and are considered candidates fro a surgical procedure to biopsy or remove the brain tumor or other tissue type at Vanderbilt University Medical Center. * Age 2 to 85
Exclusion criteria
* Patient or guardian that is unable to understand the informed consent process.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measurement of proteomic signatures in brain tumor samples | immediately upon analysis of the sample | measurement of proteomic signatures in brain tumor samples for unique protein signatures |
Countries
United States
Outcome results
None listed